Damora Therapeutics (DMRA) Other Operating Expenses (2019 - 2025)

Damora Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at $174.3 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses rose 3866.1% year-over-year to $174.3 million; the trailing twelve-month figure through Mar 2026 stood at $174.3 million (up 3150.23% YoY), and the FY2025 full-year result was $174.3 million, up 3150.23% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $174.3 million, up from $4.4 million in the prior quarter.
• The five-year high for Other Operating Expenses was $174.3 million in Q4 2025, with the low at $720000.0 in Q4 2023.
• Historically, Other Operating Expenses has averaged $36.6 million across 3 years, with a median of $2.7 million in 2023.
• Annual changes were most pronounced in 2024 — Other Operating Expenses jumped 510.42% — and 2025, when it surged 3866.1%.
• Damora Therapeutics' Other Operating Expenses stood at $720000.0 in 2023, then jumped by 510.42% to $4.4 million in 2024, then surged by 3866.1% to $174.3 million in 2025.
• The last three Other Operating Expenses figures came in at $174.3 million (Q4 2025), $4.4 million (Q4 2024), and $968000.0 (Q2 2024), per Business Quant data.